BACKGROUND: @entity470 ( @entity470 ) is a new target for @entity189 ( @entity189 ) therapy. This prospective phase I study sought to determine the safety and recommended phase II dose of @entity41059 , a novel highly selective oral @entity470 @entity4149 kinase inhibitor, in combination with intensity-modulated radiotherapy (IMRT) in @entity1 with @entity189 . METHODS: Eligible @entity1 with @entity189 received escalating doses of @entity41059 during IMRT. We treated six @entity1 at a particular dose level until the maximum tolerated dose (MTD) was determined. The starting dose was 125 mg, once-daily and the dose was escalated to another level 125 mg, twice- and thrice- daily, until dose-limiting @entity137 (DLT) occurred in two or more @entity1 at a dose level. Expression and mutation analysis of @entity470 were performed in all cases. RESULTS: A total of twelve @entity1 were enrolled. Three @entity1 experienced DLT (250 mg/day cohort) and MTD was 125 mg/day. @entity137 appears to be the major DLT. While @entity470 expression in @entity5 tissue was detected in 75% (9/12) @entity1 , @entity470 mutation was detected in 16.67% (1/6) @entity1 in 125 mg/day cohort, and 50% (3/6) in 250 mg/day cohort. CONCLUSION: The combination of @entity41059 (125 mg/day) and IMRT in @entity1 with locally @entity189 had an acceptable safety profile and was well tolerated.

Phase I study of @entity41059 , an @entity470 XXXX kinase inhibitor combined with IMRT in @entity189 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Mucositis toxicity'] @entity470 :: ('1956', 'Gene') :: ['Epidermal growth factor receptor', 'EGFR'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity189 :: ('MESH:D002277', 'Disease') :: ['nasopharyngeal carcinoma', 'NPC'] @entity41059 :: ('MESH:C531470', 'Chemical') :: ['icotinib'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine']
@entity4149 :: (D014443,Chemical) :: ['tyrosine']
